J&J, Vivus patent suit ends

Share this article:

Johnson & Johnson's Janssen subsidiary has walked away from a lawsuit against drugmaker Vivus over patents using the anti-seizure medication topiramate for a variety of medical conditions.

Vivus, in turn, has agreed to pay a one-time fee and royalty on its FDA-approved weight-loss drug Qsymia, which combines phentermine and topiramate.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters